In 2019, the global Drugs for Treating Mental Disorders market size was US$ xx million and it is expected to reach US$ xx million by the end of 2026, with a CAGR of xx% during 2020-2026.
Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost 100 countries around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Drugs for Treating Mental Disorders market in 2020. The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future.
This report also analyzes the impact of Coronavirus COVID-19 on the Drugs for Treating Mental Disorders industry.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Drugs for Treating Mental Disorders market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Drugs for Treating Mental Disorders market in terms of revenue.
Players, stakeholders, and other participants in the global Drugs for Treating Mental Disorders market will be able to gain the upper hand as they use the report as a powerful resource. For this version of the report, the segmental analysis focuses on revenue and forecast by each application segment in terms of revenue and forecast by each type segment in terms of revenue for the period 2015-2026.
Regional and Country-level Analysis
The report offers an exhaustive geographical analysis of the global Drugs for Treating Mental Disorders market, covering important regions, viz, North America, Europe, China and Japan. It also covers key countries (regions), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, UAE, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by each application segment in terms of revenue for the period 2015-2026.
Competition Analysis
In the competitive analysis section of the report, leading as well as prominent players of the global Drugs for Treating Mental Disorders market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2015-2020.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Drugs for Treating Mental Disorders market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Drugs for Treating Mental Disorders market.
The following players are covered in this report:
Johnson and Johnson
Pfizer
Eli Lilly
GlaxoSmithKline
AstraZeneca
Bristol-Myers Squibb
Teva Pharmaceutical
Dr. Reddy's Laboratories
Apotex Inc.
Mylan Pharmaceuticals
Par Pharmaceutical
Aurobindo Pharma
Torrent Pharmaceuticals
Jubilant Lifesciences
Sun Pharmaceutical
Sandoz (Novartis)
Hansoh Pharmaceutical
WATSON Pharmaceuticals
Zhejiang Langhua Pharmaceuticals
Forest Laboratories
H.Lundbeck A/S
Amneal Pharmaceuticals
Hetero Drugs
Macleods Pharmaceuticals
Silarx Pharmacueticals
Hikma Pharmaceuticals
Lupin Limited
Prinston Pharmaceutical
STI Pharma
Drugs for Treating Mental Disorders Breakdown Data by Type
Tablets
Capsule
Injection
Solution
Other
Drugs for Treating Mental Disorders Breakdown Data by Application
Antipsychotics
Antidepressants
Antianxiety (Anxiolyitcs)
Anti-Seizure Medications
Stimulants
Cognitive Disorders And Dementia
Sleep Disorder Treatments
Substance Abuse Treatments
Hypnosis And Tranquilizers
Other
Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost 100 countries around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Drugs for Treating Mental Disorders market in 2020. The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future.
This report also analyzes the impact of Coronavirus COVID-19 on the Drugs for Treating Mental Disorders industry.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Drugs for Treating Mental Disorders market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Drugs for Treating Mental Disorders market in terms of revenue.
Players, stakeholders, and other participants in the global Drugs for Treating Mental Disorders market will be able to gain the upper hand as they use the report as a powerful resource. For this version of the report, the segmental analysis focuses on revenue and forecast by each application segment in terms of revenue and forecast by each type segment in terms of revenue for the period 2015-2026.
Regional and Country-level Analysis
The report offers an exhaustive geographical analysis of the global Drugs for Treating Mental Disorders market, covering important regions, viz, North America, Europe, China and Japan. It also covers key countries (regions), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, UAE, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by each application segment in terms of revenue for the period 2015-2026.
Competition Analysis
In the competitive analysis section of the report, leading as well as prominent players of the global Drugs for Treating Mental Disorders market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2015-2020.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Drugs for Treating Mental Disorders market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Drugs for Treating Mental Disorders market.
The following players are covered in this report:
Johnson and Johnson
Pfizer
Eli Lilly
GlaxoSmithKline
AstraZeneca
Bristol-Myers Squibb
Teva Pharmaceutical
Dr. Reddy's Laboratories
Apotex Inc.
Mylan Pharmaceuticals
Par Pharmaceutical
Aurobindo Pharma
Torrent Pharmaceuticals
Jubilant Lifesciences
Sun Pharmaceutical
Sandoz (Novartis)
Hansoh Pharmaceutical
WATSON Pharmaceuticals
Zhejiang Langhua Pharmaceuticals
Forest Laboratories
H.Lundbeck A/S
Amneal Pharmaceuticals
Hetero Drugs
Macleods Pharmaceuticals
Silarx Pharmacueticals
Hikma Pharmaceuticals
Lupin Limited
Prinston Pharmaceutical
STI Pharma
Drugs for Treating Mental Disorders Breakdown Data by Type
Tablets
Capsule
Injection
Solution
Other
Drugs for Treating Mental Disorders Breakdown Data by Application
Antipsychotics
Antidepressants
Antianxiety (Anxiolyitcs)
Anti-Seizure Medications
Stimulants
Cognitive Disorders And Dementia
Sleep Disorder Treatments
Substance Abuse Treatments
Hypnosis And Tranquilizers
Other
1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Drugs for Treating Mental Disorders Revenue
1.4 Market Analysis by Type
1.4.1 Global Drugs for Treating Mental Disorders Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Tablets
1.4.3 Capsule
1.4.4 Injection
1.4.5 Solution
1.4.6 Other
1.5 Market by Application
1.5.1 Global Drugs for Treating Mental Disorders Market Size Growth Rate by Application: 2020 VS 2026
1.5.2 Antipsychotics
1.5.3 Antidepressants
1.5.4 Antianxiety (Anxiolyitcs)
1.5.5 Anti-Seizure Medications
1.5.6 Stimulants
1.5.7 Cognitive Disorders And Dementia
1.5.8 Sleep Disorder Treatments
1.5.9 Substance Abuse Treatments
1.5.10 Hypnosis And Tranquilizers
1.5.11 Other
1.6 Coronavirus Disease 2019 (Covid-19): Drugs for Treating Mental Disorders Industry Impact
1.6.1 How the Covid-19 is Affecting the Drugs for Treating Mental Disorders Industry
1.6.1.1 Drugs for Treating Mental Disorders Business Impact Assessment - Covid-19
1.6.1.2 Supply Chain Challenges
1.6.1.3 COVID-19’s Impact On Crude Oil and Refined Products
1.6.2 Market Trends and Drugs for Treating Mental Disorders Potential Opportunities in the COVID-19 Landscape
1.6.3 Measures / Proposal against Covid-19
1.6.3.1 Government Measures to Combat Covid-19 Impact
1.6.3.2 Proposal for Drugs for Treating Mental Disorders Players to Combat Covid-19 Impact
1.7 Study Objectives
1.8 Years Considered
2 Global Growth Trend
2.1 Global Drugs for Treating Mental Disorders Market Perspective (2015-2026)
2.2 Drugs for Treating Mental Disorders Growth Trends by Regions
2.2.1 Drugs for Treating Mental Disorders Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Drugs for Treating Mental Disorders Historic Market Size by Regions (2015-2020)
2.2.3 Drugs for Treating Mental Disorders Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Drugs for Treating Mental Disorders Market Growth Strategy
2.3.6 Primary Interviews with Key Drugs for Treating Mental Disorders Players (Opinion Leaders)
3 Competitor Landscape by Key Players
3.1 Global Top Drugs for Treating Mental Disorders Players by Market Size
3.1.1 Global Top Drugs for Treating Mental Disorders Players by Revenue (2015-2020)
3.1.2 Global Drugs for Treating Mental Disorders Revenue Market Share by Players (2015-2020)
3.1.3 Global Drugs for Treating Mental Disorders Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Drugs for Treating Mental Disorders Market Concentration Ratio
3.2.1 Global Drugs for Treating Mental Disorders Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 5 and Top 10 Players by Drugs for Treating Mental Disorders Revenue in 2019
3.3 Drugs for Treating Mental Disorders Key Players Head office and Area Served
3.4 Key Players Drugs for Treating Mental Disorders Product Solution and Service
3.5 Date of Enter into Drugs for Treating Mental Disorders Market
3.6 Mergers & Acquisitions, Expansion Plans
4 Global Drugs for Treating Mental Disorders Breakdown Data by Type (2015-2026)
4.1 Global Drugs for Treating Mental Disorders Historic Market Size by Type (2015-2020)
4.2 Global Drugs for Treating Mental Disorders Forecasted Market Size by Type (2021-2026)
5 Global Drugs for Treating Mental Disorders Breakdown Data by Application (2015-2026)
5.1 Global Drugs for Treating Mental Disorders Historic Market Size by Application (2015-2020)
5.2 Drugs for Treating Mental Disorders Forecasted Market Size by Application (2021-2026)
6 North America
6.1 North America Drugs for Treating Mental Disorders Market Size (2015-2026)
6.2 Key Drugs for Treating Mental Disorders Players Market Share in North America (2019-2020)
6.3 North America Drugs for Treating Mental Disorders Market Size by Country
6.3.1 North America Drugs for Treating Mental Disorders Sales by Country
6.3.2 North America Drugs for Treating Mental Disorders Market Size Forecast by Country (2021-2026)
6.4 U.S. Market Size Analysis
6.4.1 U.S. Drugs for Treating Mental Disorders Market Size (2015-2026)
6.4.2 U.S. Drugs for Treating Mental Disorders Market Size by Type (2015-2026)
6.4.3 U.S. Drugs for Treating Mental Disorders Market Size by Application (2015-2026)
6.5 Canada Market Size Analysis
6.5.1 Canada Drugs for Treating Mental Disorders Market Size (2015-2026)
6.5.2 Canada Drugs for Treating Mental Disorders Market Size by Type (2015-2026)
6.5.3 Canada Drugs for Treating Mental Disorders Market Size by Application (2015-2026)
7 Europe
7.1 Europe Drugs for Treating Mental Disorders Market Size (2015-2026)
7.2 Key Drugs for Treating Mental Disorders Players Market Share in Europe (2019-2020)
7.3 Europe Drugs for Treating Mental Disorders Market Size by Country
7.3.1 Europe Drugs for Treating Mental Disorders Sales by Country
7.3.2 Europe Drugs for Treating Mental Disorders Market Size Forecast by Country (2021-2026)
7.4 Germany Market Size Analysis
7.4.1 Germany Drugs for Treating Mental Disorders Market Size (2015-2026)
7.4.2 Germany Drugs for Treating Mental Disorders Market Size by Type (2015-2026)
7.4.3 Germany Drugs for Treating Mental Disorders Market Size by Application (2015-2026)
7.5 France Market Size Analysis
7.5.1 France Drugs for Treating Mental Disorders Market Size (2015-2026)
7.5.2 France Drugs for Treating Mental Disorders Market Size by Type (2015-2026)
7.5.3 France Drugs for Treating Mental Disorders Market Size by Application (2015-2026)
7.6 U.K. Market Size Analysis
7.6.1 U.K. Drugs for Treating Mental Disorders Market Size (2015-2026)
7.6.2 U.K. Drugs for Treating Mental Disorders Market Size by Type (2015-2026)
7.6.3 U.K. Drugs for Treating Mental Disorders Market Size by Application (2015-2026)
7.7 Italy Market Size Analysis
7.7.1 Italy Drugs for Treating Mental Disorders Market Size (2015-2026)
7.7.2 Italy Drugs for Treating Mental Disorders Market Size by Type (2015-2026)
7.7.3 Italy Drugs for Treating Mental Disorders Market Size by Application (2015-2026)
7.8 Russia Market Size Analysis
7.8.1 Russia Drugs for Treating Mental Disorders Market Size (2015-2026)
7.8.2 Russia Drugs for Treating Mental Disorders Market Size by Type (2015-2026)
7.8.3 Russia Drugs for Treating Mental Disorders Market Size by Application (2015-2026)
8 Asia-Pacific
8.1 Asia-Pacific Drugs for Treating Mental Disorders Market Size (2015-2026)
8.2 Key Drugs for Treating Mental Disorders Players Market Share in Asia-Pacific (2019-2020)
8.3 Asia-Pacific Drugs for Treating Mental Disorders Market Size by Country
8.3.1 Asia-Pacific Drugs for Treating Mental Disorders Sales by Country
8.3.2 Asia-Pacific Drugs for Treating Mental Disorders Market Size Forecast by Country (2021-2026)
8.4 China Market Size Analysis
8.4.1 China Drugs for Treating Mental Disorders Market Size (2015-2026)
8.4.2 China Drugs for Treating Mental Disorders Market Size by Type (2015-2026)
8.4.3 China Drugs for Treating Mental Disorders Market Size by Application (2015-2026)
8.5 Japan Market Size Analysis
8.5.1 Japan Drugs for Treating Mental Disorders Market Size (2015-2026)
8.5.2 Japan Drugs for Treating Mental Disorders Market Size by Type (2015-2026)
8.5.3 Japan Drugs for Treating Mental Disorders Market Size by Application (2015-2026)
8.6 South Korea Market Size Analysis
8.6.1 South Korea Drugs for Treating Mental Disorders Market Size (2015-2026)
8.6.2 South Korea Drugs for Treating Mental Disorders Market Size by Type (2015-2026)
8.6.3 South Korea Drugs for Treating Mental Disorders Market Size by Application (2015-2026)
8.7 India Market Size Analysis
8.7.1 India Drugs for Treating Mental Disorders Market Size (2015-2026)
8.7.2 India Drugs for Treating Mental Disorders Market Size by Type (2015-2026)
8.7.3 India Drugs for Treating Mental Disorders Market Size by Application (2015-2026)
8.8 Australia Market Size Analysis
8.8.1 Australia Drugs for Treating Mental Disorders Market Size (2015-2026)
8.8.2 Australia Drugs for Treating Mental Disorders Market Size by Type (2015-2026)
8.8.3 Australia Drugs for Treating Mental Disorders Market Size by Application (2015-2026)
8.9 Taiwan Market Size Analysis
8.9.1 Taiwan Drugs for Treating Mental Disorders Market Size (2015-2026)
8.9.2 Taiwan Drugs for Treating Mental Disorders Market Size by Type (2015-2026)
8.9.3 Taiwan Drugs for Treating Mental Disorders Market Size by Application (2015-2026)
8.10 Indonesia Market Size Analysis
8.10.1 Indonesia Drugs for Treating Mental Disorders Market Size (2015-2026)
8.10.2 Indonesia Drugs for Treating Mental Disorders Market Size by Type (2015-2026)
8.10.3 Indonesia Drugs for Treating Mental Disorders Market Size by Application (2015-2026)
8.11 Thailand Market Size Analysis
8.11.1 Thailand Drugs for Treating Mental Disorders Market Size (2015-2026)
8.11.2 Thailand Drugs for Treating Mental Disorders Market Size by Type (2015-2026)
8.11.3 Thailand Drugs for Treating Mental Disorders Market Size by Application (2015-2026)
8.12 Malaysia Market Size Analysis
8.12.1 Malaysia Drugs for Treating Mental Disorders Market Size (2015-2026)
8.12.2 Malaysia Drugs for Treating Mental Disorders Market Size by Type (2015-2026)
8.12.3 Malaysia Drugs for Treating Mental Disorders Market Size by Application (2015-2026)
8.13 Philippines Market Size Analysis
8.13.1 Philippines Drugs for Treating Mental Disorders Market Size (2015-2026)
8.13.2 Philippines Drugs for Treating Mental Disorders Market Size by Type (2015-2026)
8.13.3 Philippines Drugs for Treating Mental Disorders Market Size by Application (2015-2026)
8.14 Vietnam Market Size Analysis
8.14.1 Vietnam Drugs for Treating Mental Disorders Market Size (2015-2026)
8.14.2 Vietnam Drugs for Treating Mental Disorders Market Size by Type (2015-2026)
8.14.3 Vietnam Drugs for Treating Mental Disorders Market Size by Application (2015-2026)
9 Latin America
9.1 Latin America Drugs for Treating Mental Disorders Market Size (2015-2026)
9.2 Key Drugs for Treating Mental Disorders Players Market Share in Latin America (2019-2020)
9.3 Latin America Drugs for Treating Mental Disorders Market Size by Country
9.3.1 Latin America Drugs for Treating Mental Disorders Sales by Country
9.3.2 Latin America Drugs for Treating Mental Disorders Market Size Forecast by Country (2021-2026)
9.4 Mexico Market Size Analysis
9.4.1 Mexico Drugs for Treating Mental Disorders Market Size (2015-2026)
9.4.2 Mexico Drugs for Treating Mental Disorders Market Size by Type (2015-2026)
9.4.3 Mexico Drugs for Treating Mental Disorders Market Size by Application (2015-2026)
9.5 Brazil Market Size Analysis
9.5.1 Brazil Drugs for Treating Mental Disorders Market Size (2015-2026)
9.5.2 Brazil Drugs for Treating Mental Disorders Market Size by Type (2015-2026)
9.5.3 Brazil Drugs for Treating Mental Disorders Market Size by Application (2015-2026)
9.6 Argentina Market Size Analysis
9.6.1 Argentina Drugs for Treating Mental Disorders Market Size (2015-2026)
9.6.2 Argentina Drugs for Treating Mental Disorders Market Size by Type (2015-2026)
9.6.3 Argentina Drugs for Treating Mental Disorders Market Size by Application (2015-2026)
10 Middle East & Africa
10.1 Middle East & Africa Drugs for Treating Mental Disorders Market Size (2015-2026)
10.2 Key Drugs for Treating Mental Disorders Players Market Share in Middle East & Africa (2019-2020)
10.3 Middle East & Africa Drugs for Treating Mental Disorders Market Size by Country
10.3.1 Middle East & Africa Drugs for Treating Mental Disorders Sales by Country
10.3.2 Middle East & Africa Drugs for Treating Mental Disorders Market Size Forecast by Country (2021-2026)
10.4 Turkey Market Size Analysis
10.4.1 Turkey Drugs for Treating Mental Disorders Market Size (2015-2026)
10.4.2 Turkey Drugs for Treating Mental Disorders Market Size by Type (2015-2026)
10.4.3 Turkey Drugs for Treating Mental Disorders Market Size by Application (2015-2026)
10.5 Saudi Arabia Market Size Analysis
10.5.1 Saudi Arabia Drugs for Treating Mental Disorders Market Size (2015-2026)
10.5.2 Saudi Arabia Drugs for Treating Mental Disorders Market Size by Type (2015-2026)
10.5.3 Saudi Arabia Drugs for Treating Mental Disorders Market Size by Application (2015-2026)
10.6 UAE Market Size Analysis
10.6.1 UAE Drugs for Treating Mental Disorders Market Size (2015-2026)
10.6.2 UAE Drugs for Treating Mental Disorders Market Size by Type (2015-2026)
10.6.3 UAE Drugs for Treating Mental Disorders Market Size by Application (2015-2026)
11 Company Profiles
11.1 Johnson and Johnson
11.1.1 Johnson and Johnson Company Details
11.1.2 Johnson and Johnson Business Overview and Its Total Revenue
11.1.3 Johnson and Johnson Introduction
11.1.4 Johnson and Johnson Revenue in Drugs for Treating Mental Disorders Business (2015-2020)
11.1.5 Johnson and Johnson Recent Development
11.2 Pfizer
11.2.1 Pfizer Company Details
11.2.2 Pfizer Business Overview and Its Total Revenue
11.2.3 Pfizer Introduction
11.2.4 Pfizer Revenue in Drugs for Treating Mental Disorders Business (2015-2020)
11.2.5 Pfizer Recent Development
11.3 Eli Lilly
11.3.1 Eli Lilly Company Details
11.3.2 Eli Lilly Business Overview and Its Total Revenue
11.3.3 Eli Lilly Introduction
11.3.4 Eli Lilly Revenue in Drugs for Treating Mental Disorders Business (2015-2020)
11.3.5 Eli Lilly Recent Development
11.4 GlaxoSmithKline
11.4.1 GlaxoSmithKline Company Details
11.4.2 GlaxoSmithKline Business Overview and Its Total Revenue
11.4.3 GlaxoSmithKline Introduction
11.4.4 GlaxoSmithKline Revenue in Drugs for Treating Mental Disorders Business (2015-2020)
11.4.5 GlaxoSmithKline Recent Development
11.5 AstraZeneca
11.5.1 AstraZeneca Company Details
11.5.2 AstraZeneca Business Overview and Its Total Revenue
11.5.3 AstraZeneca Introduction
11.5.4 AstraZeneca Revenue in Drugs for Treating Mental Disorders Business (2015-2020)
11.5.5 AstraZeneca Recent Development
11.6 Bristol-Myers Squibb
11.6.1 Bristol-Myers Squibb Company Details
11.6.2 Bristol-Myers Squibb Business Overview and Its Total Revenue
11.6.3 Bristol-Myers Squibb Introduction
11.6.4 Bristol-Myers Squibb Revenue in Drugs for Treating Mental Disorders Business (2015-2020)
11.6.5 Bristol-Myers Squibb Recent Development
11.7 Teva Pharmaceutical
11.7.1 Teva Pharmaceutical Company Details
11.7.2 Teva Pharmaceutical Business Overview and Its Total Revenue
11.7.3 Teva Pharmaceutical Introduction
11.7.4 Teva Pharmaceutical Revenue in Drugs for Treating Mental Disorders Business (2015-2020)
11.7.5 Teva Pharmaceutical Recent Development
11.8 Dr. Reddy's Laboratories
11.8.1 Dr. Reddy's Laboratories Company Details
11.8.2 Dr. Reddy's Laboratories Business Overview and Its Total Revenue
11.8.3 Dr. Reddy's Laboratories Introduction
11.8.4 Dr. Reddy's Laboratories Revenue in Drugs for Treating Mental Disorders Business (2015-2020)
11.8.5 Dr. Reddy's Laboratories Recent Development
11.9 Apotex Inc.
11.9.1 Apotex Inc. Company Details
11.9.2 Apotex Inc. Business Overview and Its Total Revenue
11.9.3 Apotex Inc. Introduction
11.9.4 Apotex Inc. Revenue in Drugs for Treating Mental Disorders Business (2015-2020)
11.9.5 Apotex Inc. Recent Development
11.10 Mylan Pharmaceuticals
11.10.1 Mylan Pharmaceuticals Company Details
11.10.2 Mylan Pharmaceuticals Business Overview and Its Total Revenue
11.10.3 Mylan Pharmaceuticals Introduction
11.10.4 Mylan Pharmaceuticals Revenue in Drugs for Treating Mental Disorders Business (2015-2020)
11.10.5 Mylan Pharmaceuticals Recent Development
11.11 Par Pharmaceutical
11.11.1 Par Pharmaceutical Company Details
11.11.2 Par Pharmaceutical Business Overview and Its Total Revenue
11.11.3 Par Pharmaceutical Introduction
11.11.4 Par Pharmaceutical Revenue in Drugs for Treating Mental Disorders Business (2015-2020)
11.11.5 Par Pharmaceutical Recent Development
11.12 Aurobindo Pharma
11.12.1 Aurobindo Pharma Company Details
11.12.2 Aurobindo Pharma Business Overview and Its Total Revenue
11.12.3 Aurobindo Pharma Introduction
11.12.4 Aurobindo Pharma Revenue in Drugs for Treating Mental Disorders Business (2015-2020)
11.12.5 Aurobindo Pharma Recent Development
11.13 Torrent Pharmaceuticals
11.13.1 Torrent Pharmaceuticals Company Details
11.13.2 Torrent Pharmaceuticals Business Overview and Its Total Revenue
11.13.3 Torrent Pharmaceuticals Introduction
11.13.4 Torrent Pharmaceuticals Revenue in Drugs for Treating Mental Disorders Business (2015-2020)
11.13.5 Torrent Pharmaceuticals Recent Development
11.14 Jubilant Lifesciences
11.14.1 Jubilant Lifesciences Company Details
11.14.2 Jubilant Lifesciences Business Overview and Its Total Revenue
11.14.3 Jubilant Lifesciences Introduction
11.14.4 Jubilant Lifesciences Revenue in Drugs for Treating Mental Disorders Business (2015-2020)
11.14.5 Jubilant Lifesciences Recent Development
11.15 Sun Pharmaceutical
11.15.1 Sun Pharmaceutical Company Details
11.15.2 Sun Pharmaceutical Business Overview and Its Total Revenue
11.15.3 Sun Pharmaceutical Introduction
11.15.4 Sun Pharmaceutical Revenue in Drugs for Treating Mental Disorders Business (2015-2020)
11.15.5 Sun Pharmaceutical Recent Development
11.16 Sandoz (Novartis)
11.16.1 Sandoz (Novartis) Company Details
11.16.2 Sandoz (Novartis) Business Overview and Its Total Revenue
11.16.3 Sandoz (Novartis) Introduction
11.16.4 Sandoz (Novartis) Revenue in Drugs for Treating Mental Disorders Business (2015-2020)
11.16.5 Sandoz (Novartis) Recent Development
11.17 Hansoh Pharmaceutical
11.17.1 Hansoh Pharmaceutical Company Details
11.17.2 Hansoh Pharmaceutical Business Overview and Its Total Revenue
11.17.3 Hansoh Pharmaceutical Introduction
11.17.4 Hansoh Pharmaceutical Revenue in Drugs for Treating Mental Disorders Business (2015-2020)
11.17.5 Hansoh Pharmaceutical Recent Development
11.18 WATSON Pharmaceuticals
11.18.1 WATSON Pharmaceuticals Company Details
11.18.2 WATSON Pharmaceuticals Business Overview and Its Total Revenue
11.18.3 WATSON Pharmaceuticals Introduction
11.18.4 WATSON Pharmaceuticals Revenue in Drugs for Treating Mental Disorders Business (2015-2020)
11.18.5 WATSON Pharmaceuticals Recent Development
11.19 Zhejiang Langhua Pharmaceuticals
11.19.1 Zhejiang Langhua Pharmaceuticals Company Details
11.19.2 Zhejiang Langhua Pharmaceuticals Business Overview and Its Total Revenue
11.19.3 Zhejiang Langhua Pharmaceuticals Introduction
11.19.4 Zhejiang Langhua Pharmaceuticals Revenue in Drugs for Treating Mental Disorders Business (2015-2020)
11.19.5 Zhejiang Langhua Pharmaceuticals Recent Development
11.20 Forest Laboratories
11.20.1 Forest Laboratories Company Details
11.20.2 Forest Laboratories Business Overview and Its Total Revenue
11.20.3 Forest Laboratories Introduction
11.20.4 Forest Laboratories Revenue in Drugs for Treating Mental Disorders Business (2015-2020)
11.20.5 Forest Laboratories Recent Development
11.21 H.Lundbeck A/S
11.21.1 H.Lundbeck A/S Company Details
11.21.2 H.Lundbeck A/S Business Overview and Its Total Revenue
11.21.3 H.Lundbeck A/S Introduction
11.21.4 H.Lundbeck A/S Revenue in Drugs for Treating Mental Disorders Business (2015-2020)
11.21.5 H.Lundbeck A/S Recent Development
11.22 Amneal Pharmaceuticals
11.22.1 Amneal Pharmaceuticals Company Details
11.22.2 Amneal Pharmaceuticals Business Overview and Its Total Revenue
11.22.3 Amneal Pharmaceuticals Introduction
11.22.4 Amneal Pharmaceuticals Revenue in Drugs for Treating Mental Disorders Business (2015-2020)
11.22.5 Amneal Pharmaceuticals Recent Development
11.23 Hetero Drugs
11.23.1 Hetero Drugs Company Details
11.23.2 Hetero Drugs Business Overview and Its Total Revenue
11.23.3 Hetero Drugs Introduction
11.23.4 Hetero Drugs Revenue in Drugs for Treating Mental Disorders Business (2015-2020)
11.23.5 Hetero Drugs Recent Development
11.24 Macleods Pharmaceuticals
11.24.1 Macleods Pharmaceuticals Company Details
11.24.2 Macleods Pharmaceuticals Business Overview and Its Total Revenue
11.24.3 Macleods Pharmaceuticals Introduction
11.24.4 Macleods Pharmaceuticals Revenue in Drugs for Treating Mental Disorders Business (2015-2020)
11.24.5 Macleods Pharmaceuticals Recent Development
11.25 Silarx Pharmacueticals
11.25.1 Silarx Pharmacueticals Company Details
11.25.2 Silarx Pharmacueticals Business Overview and Its Total Revenue
11.25.3 Silarx Pharmacueticals Introduction
11.25.4 Silarx Pharmacueticals Revenue in Drugs for Treating Mental Disorders Business (2015-2020)
11.25.5 Silarx Pharmacueticals Recent Development
11.26 Hikma Pharmaceuticals
11.26.1 Hikma Pharmaceuticals Company Details
11.26.2 Hikma Pharmaceuticals Business Overview and Its Total Revenue
11.26.3 Hikma Pharmaceuticals Introduction
11.26.4 Hikma Pharmaceuticals Revenue in Drugs for Treating Mental Disorders Business (2015-2020)
11.26.5 Hikma Pharmaceuticals Recent Development
11.27 Lupin Limited
11.27.1 Lupin Limited Company Details
11.27.2 Lupin Limited Business Overview and Its Total Revenue
11.27.3 Lupin Limited Introduction
11.27.4 Lupin Limited Revenue in Drugs for Treating Mental Disorders Business (2015-2020)
11.27.5 Lupin Limited Recent Development
11.28 Prinston Pharmaceutical
11.28.1 Prinston Pharmaceutical Company Details
11.28.2 Prinston Pharmaceutical Business Overview and Its Total Revenue
11.28.3 Prinston Pharmaceutical Introduction
11.28.4 Prinston Pharmaceutical Revenue in Drugs for Treating Mental Disorders Business (2015-2020)
11.28.5 Prinston Pharmaceutical Recent Development
11.29 STI Pharma
11.29.1 STI Pharma Company Details
11.29.2 STI Pharma Business Overview and Its Total Revenue
11.29.3 STI Pharma Introduction
11.29.4 STI Pharma Revenue in Drugs for Treating Mental Disorders Business (2015-2020)
11.29.5 STI Pharma Recent Development
12 Analyst's Viewpoints/Conclusion
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
